多发性骨髓瘤中源自更早期未分选干细胞产品的 CAR-T 细胞功能与线粒体适应性增强

Chimeric antigen receptor T (CAR-T) cells targeting B cell maturation antigen (BCMA) have changed the treatment landscape for patients with relapsed and refractory multiple myeloma.

However, T cell dysfunction associated with progressive disease and multiple prior lines of therapy (PLOT) raises concerns about the feasibility of consistently manufacturing effective CAR-T cells.

We investigated the practicality of utilizing previously cryopreserved mobilized apheresis to generate potent anti-BCMA CAR-T cells. Paired patient samples collected longitudinally from (1) mobilized, unfractionated apheresis obtained before hematopoietic cell transplantation (mobHCT) and (2) apheresis obtained for commercial CAR-T manufacture (aphCAR) were directly compared head to head. The median time from transplant to commercial CAR-T infusion was 4. 2 years (range, 2. 5-12.

5 years), and before CAR-T collection all patients were triple-class exposed. Analysis revealed that mobHCT samples exhibited a higher CD4:CD8 ratio and a greater proportion of naive T cells (CCR7 + CD45RO - ) in both CD4 and CD8 compartments compared with aphCAR samples. CAR-T cells derived from mobHCT samples demonstrated superior expansion during manufacturing, enhanced interleukin-2 secretion, reduced expression of checkpoint inhibitors, improved cytotoxicity through multiple stimulation rounds, and enhanced mitochondrial function.

These findings underscore the potential of utilizing cryopreserved mobilized apheresis collected earlier in the disease course to produce potent and metabolically robust CAR-T cells.